U.S. FDA Approves INREBIC (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis

Press/Media: Press / Media

PeriodAug 16 2019

Media coverage

2

Media coverage

  • TitleU.S. FDA Approves INREBIC (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
    Media name/outletWallstreet Online
    CountryGermany
    Date8/16/19
    PersonsRuben Mesa
  • TitleU.S. FDA Approves INREBIC (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
    Media name/outletPressReleasePoint
    CountryIndia
    Date8/16/19
    PersonsRuben Mesa